Predictors of change in adherence status from 1 year to the next among patients with type 2 diabetes mellitus on oral antidiabetes drugs

Journal of Managed Care and Specialty Pharmacy

Volumn 22, Issue 5, 2016, Pages 467-482

  Saundankar, Vishal ^a,b   Peng, Xiaomei ^c   Fu, Haoda Fu ^d   Ascher Svanum, Haya ^d   Rodriguez, Angel ^e   Ali, Ayad ^f   Slabaugh, Lane ^g   Young, Peinie ^g   Louder, Anthony ^g  

^a Formerly of Comprehensive Health Insights Inc   (United States)

^b Comprensive Health Insights ^*  (United States)

^c Global Patient Outcomes and Real World Evidence   (United States)

^d Statistics   (United States)

^e ELI LILLY AND COMPANY   (United States)

^f Medical Diabetes   (Spain)

^g HUMANA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

AGED; COST BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LONGITUDINAL STUDY; MALE; MEDICATION COMPLIANCE; METABOLISM; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA;

AGED; BLOOD GLUCOSE; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LONGITUDINAL STUDIES; MALE; MEDICATION ADHERENCE; RETROSPECTIVE STUDIES;

EID: 84969626038     PISSN: 23760540     EISSN: 23761032     Source Type: Journal    
DOI: 10.18553/jmcp.2016.22.5.467     Document Type: Article

References (31)

1. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care. 2008;31(3):596-615.
2. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. 2011. Available at: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf. Accessed January 26, 2016.
3. Centers for Disease Control and Prevention. National diabetes statistics report, 2014. Estimates of diabetes and its burden in the United States. Atlanta, GA: U.S. Department of Health and Human Services, 2014. Available at: http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf. Accessed January 26, 2016.
4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837-53.
5. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-12.
6. Bailey CJ, Kodack M. Patient adherence to medication requirements for therapy of type 2 diabetes. Int J Clin Pract. 2011;65(3):314-22.
7. Hepke KL, Martus MT, Share DA. Costs and utilization associated with pharmaceutical adherence in a diabetic population. Am J Manag Care. 2004;10(2 Pt 2):144-51.
8. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27(5):1218-24.
9. Feldman BS, Cohen-Stavi CJ, Leibowitz M, et al. Defining the role of medication adherence in poor glycemic control among a general adult population with diabetes. PLoS One. 2014;9(9):e108145.
10. Trinacty CM, Adams AS, Soumerai SB, et al. Racial differences in long-term adherence to oral antidiabetic drug therapy: a longitudinal cohort study. BMC Health Serv Res. 2009;9:24.
11. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521-30.
12. National Committee for Quality Assurance (NCQA). HEDIS & Quality Measurement. HEDIS 2014, Volume 2. Summary table of measures, product lines and changes. Available at: http://www.ncqa.org/Portals/0/HEDISQM/HEDIS2014/List_of_HEDIS_2014_Measures.pdf. Accessed February 6, 2016.
13. Centers for Medicare & Medicaid Services (CMS). Quality rating system measure technical specifications. September 2014. Available at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/QualityInitiativesGenInfo/Downloads/2015-QRS-Measure-Technical-Specifications.pdf. Accessed February 6, 2016.
14. Maciejewski ML, Bryson CL, Perkins M, et al. Increasing copayments and adherence to diabetes, hypertension, and hyperlipidemic medications. Am J Manag Care. 2010;16(1):e20-34.
15. Polonsky WH, Anderson BJ, Lohrer PA, Aponte JE, Jacobson AM, Cole CF. Insulin omission in women with IDDM. Diabetes Care. 1994;17(10):1178-85.
16. Quilliam BJ, Ozbay AB, Sill BE, Kogut SJ. The association between adherence to oral anti-diabetic drugs and hypoglycaemia in persons with Type 2 diabetes. Diabet Med. 2013;30(11):1305-13.
17. Kalsekar ID, Madhavan SS, Amonkar MM, Makela EH, Scott VG, Douglas SM. Depression in patients with type 2 diabetes: impact on adherence to oral hypoglycemic agents. Ann Pharmacother. 2006;40(4):605-11.
18. Barron J, Wahl P, Fisher M, Plauschinat C. Effect of prescription copayments on adherence and treatment failure with oral antidiabetic medications. PT. 2008;33(9):532-53.
19. Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-26.
20. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol. 1992;45(2):197-203.
21. Johnson RE, Hornbrook MC, Nichols GA. Replicating the chronic disease score (CDS) from automated pharmacy data. J Clin Epidemiol. 1994;47(10):1191-99.
22. McGregor JC, Kim PW, Perencevich EN, et al. Utility of the Chronic Disease Score and Charlson Comorbidity Index as comorbidity measures for use in epidemiologic studies of antibiotic-resistant organisms. Am J Epidemiol. 2005;161(5):483-93.
23. Sloan KL, Sales AE, Liu CF, et al. Construction and characteristics of the RxRisk-V: a VA-adapted pharmacy-based case-mix instrument. Med Care. 2003;41(6):761-74.
24. Sales AE, Liu CF, Sloan KL, et al. Predicting costs of care using a pharmacy-based measure risk adjustment in a veteran population. Med Care. 2003;41(6):753-60.
25. Fishman PA, Goodman MJ, Hornbrook MC, Meenan RT, Bachman DJ, O'Keeffe Rosetti MC. Risk adjustment using automated ambulatory pharmacy data: the RxRisk model. Med Care. 2003;41(1):84-99.
26. Hastie T, Tibshirani R, Friedman J. The Elements of Statistical Learning: Data Mining, Inference, and Prediction. 2nd ed. New York: Springer; 2009.
27. Sinnott SJ, Buckley C, O'Riordan D, Bradley C, Whelton H. The effect of copayments for prescriptions on adherence to prescription medicines in publicly insured populations; a systematic review and meta-analysis. PLoS One. 2013;8(5):e64914.
28. Colombi AM, Yu-Isenberg K, Priest J. The effects of health plan copayments on adherence to oral diabetes medication and health resource utilization. J Occup Environ Med. 2008;50(5):535-41.
29. Steiner JF, Ho PM, Beaty BL, et al. Socio-demographic and clinical characteristics are not clinically useful predictors of refill adherence in patients with hypertension. Circ Cardiovasc Qual Outcomes. 2009;2(5):451-57.
30. Franklin JM, Shrank WH, Pakes J, et al. Group-based trajectory models: a new approach to classifying and predicting long-term medication adherence. Med Care. 2013;51(9):789-96.
31. Peterson AM, Nau P, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 2007;10(1):3-12.